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Individuals with impaired glucose tolerance (IGT) are at increased risk for developing type 2 diabetes melli-
tus (T2DM) and cardiovascular disease, including stroke.1 
Individuals with IGT exhibit many cardiovascular disease 
risk factors found in T2DM.2 However, longitudinal stud-
ies of well-characterized IGT populations have not been 
available to examine predictors of stroke. The Nateglinide 
and Valsartan in Impaired Glucose Tolerance Outcomes 
Research trial (NAVIGATOR) provides the opportunity 
to establish the factors associated with increased risk of 
stroke in IGT.3
Methods
NAVIGATOR was a multi-continental randomized, double-blind, 
placebo-controlled trial to determine whether treatment with nateg-
linide and valsartan, respectively (2×2 factorial design), would reduce 
progression to T2DM and incident cardiovascular events, respective-
ly, in participants with IGT but not T2DM.3 A total of 9306 partici-
pants were followed for a median of 6.4 years. Doses of nateglinide 
and valsartan could be adjusted based on side-effects but not glucose 
levels or blood pressure readings, respectively. Patients with IGT 
(2-hour postchallenge glucose value, 7.8–11.0 mmol/L and fasting 
glucose, 5.3–6.9 mmol/L) were eligible if they had ≥1 cardiovascu-
lar risk factor and were aged ≥55 years or established cardiovascular 
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Table 1. Baseline Characteristics of 9306 Participants With Impaired Glucose Tolerance in NAVIGATOR Stratified by Occurrence of Stroke
Variable
Stroke During Trial
P ValueNo (n=9069) Yes (n=237)
Age (y) 64 (7) 66 (7) <0.001
Men 4454 (49) 141 (59) 0.002
Race 0.16
  Black 225 (3) 11 (5)
  White 7537 (83) 197 (83)
  Asian 601 (7) 12 (5)
  Other 706 (8) 17 (7)
Region 0.22
  North America 2101 (23) 45 (19)
  Europe 4783 (53) 126 (53)
  Asia 540 (6) 12 (5)
  Latin America 1359 (15) 47 (20)
  Other 286 (3) 7 (3)
Current smoker 994 (11) 31 (13) 0.30
Medical history
  Coronary heart disease* 2528 (28) 98 (41) <0.001
  Cerebrovascular disease† 692 (8) 44 (19) <0.001
  Peripheral arterial disease‡ 292 (3) 17 (7) 0.001
  Chronic obstructive pulmonary disease 436 (5) 15 (6) 0.28
  Heart failure 317 (4) 14 (6) 0.05
  Hypertension 7031 (78) 185 (78) 0.85
  Venous thromboembolism (pulmonary embolism/deep venous thrombosis) 116 (1) 13 (6) <0.001
  Family history of premature coronary heart disease 1499 (17) 45 (19) 0.32
  Family history of diabetes mellitus 3456 (38) 91 (38) 0.93
Clinical features
  Weight (kg) 83.6 (17.2) 84.1 (17.1) 0.58
  Body mass index (kg/m2) 30.5 (5.4) 30.3 (5.6) 0.41
  Waist circumference (cm) 101 (14) 103 (13) 0.003
  Height (cm) 165 (10) 167 (10) 0.07
  Systolic blood pressure (mm Hg) 140 (17) 145 (20) <0.001
  Diastolic blood pressure (mm Hg) 83 (10) 83 (11) 0.46
  Pulse pressure (mm Hg) 57 (14) 62 (16) <0.001
  Left ventricular hypertrophy 254 (3) 14 (6) 0.005
  Heart rate (bpm) 70 (11) 69 (12) 0.01
  Atrial fibrillation or flutter 336 (4) 20 (8) <0.001
Laboratory
  Fasting glucose (mmol/L) 6.1 (0.5) 6.1 (0.5) 0.28
  2-hour glucose (mmol/L) 9.2 (0.9) 9.2 (0.9) 0.17
  HbA1c (%) 5.8 (0.4) 5.9 (0.5) 0.011
  eGFR (mL min−1 1.73 m−2) 81 (18) 76 (20) <0.001
  Urine albumin/creatinine ratio (log units) 0.1 (1.2) 0.3 (1.2) <0.001
  LDL cholesterol (mmol/L) 3.3 (1.0) 3.3 (0.9) 0.14
  HDL cholesterol (mmol/L) 1.3 (0.3) 1.2 (0.3) 0.11
  Triglycerides (mmol/L) 1.9 (1.1) 2.0 (1.1) 0.68
  Hemoglobin (g/L) 147 (13) 146 (13) 0.61
  Sodium (mmol/L) 142 (2) 143 (3) 0.64
n (%) or mean [SD]. Not listed but also included in models: potassium, white blood cells, platelet count, and randomized treatments with nateglinide and valsartan, 
respectively. eGFR indicates estimated glomerular filtration rate; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; LDL, low-density lipoprotein; and NAVIGATOR, 
Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial.
*Previous myocardial infarction, angina, positive stress test, and coronary revascularization.
†Stroke and transient ischemic attack.
‡Limb or foot amputation, intermittent claudication, and limb arterial bypass procedure.
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disease and aged ≥50 years. Relevant qualifying cardiovascular dis-
ease risk factors are provided in previous publications.3 The trial was 
approved by local ethics committees, and participants provided writ-
ten informed consent. The end point of stroke was adjudicated by an 
independent committee and trial definitions are provided in Table I in 
the online-only Data Supplement.
Cox proportional-hazard regression models were developed for oc-
currence of stroke. Thirty-nine candidate variables were included in 
the forward model selection (P<0.05; Table 1). Randomized treatments 
(valsartan versus placebo and nateglinide versus placebo) and race 
were forced into the model. Discrimination ability was assessed with 
optimism-corrected C-statistics. P values <0.05 were considered statis-
tically significant, and all P values were 2-sided. Analyses were con-
ducted independently at the Duke Clinical Research Institute (Durham, 
NC) using SAS version 9.2 software (SAS Institute Inc, Cary, NC).
Results
Stroke occurred in 237 of the 9306 NAVIGATOR participants 
during a median follow-up of 6.4 years (202 nonhemorrhagic 
strokes). Among subjects without history of cerebrovascular 
disease (n=8570), 193 (2.3%) experienced a stroke, com-
pared with 44 (6.0%) out of 736 with a history of cerebro-
vascular disease.
Major independent predictors of stroke included previous 
venous thromboembolism (pulmonary embolism or deep 
venous thrombosis; the strongest predictor), previous cerebro-
vascular disease (stroke or transient ischemic attack), higher 
pulse pressure, and higher waist circumference (Table 2). 
Other independent predictors were previous coronary heart 
disease, higher low-density lipoprotein cholesterol, lower 
estimated glomerular filtration rate, lower heart rate (below 
a threshold of 70 bpm), lower body mass index, older age, 
the presence of atrial fibrillation, and black race versus all 
other races. No glycemic measure was associated with stroke. 
The C-statistic for the prognostic model was 0.72. Results 
were similar in the 8570 patients without a history of stroke 
at baseline (C-statistic 0.72; Table II in the online-only Data 
Supplement).
Predictors of nonhemorrhagic stroke (202 events) were 
similar to predictors of all strokes. The variables most strongly 
associated with nonhemorrhagic stroke were cerebrovascular 
disease, previous venous thromboembolism, coronary heart 
disease, higher pulse pressure, and lower estimated glomerular 
filtration rate (Table III in the online-only Data Supplement).
Discussion
In this study, we confirmed that most stroke risk factors in 
IGT were similar to those in both the general population and 
T2DM.1,4
Cigarette smoking, hypertension, age, T2DM, cholesterol, 
low high-density lipoprotein cholesterol, atrial fibrillation, 
and carotid stenosis are the recognized stroke risk factors.4 
Results from NAVIGATOR largely reflected this, although 
surprisingly current smoking status was not predictive of 
stroke. Prior venous thromboembolism (pulmonary embolism 
or deep venous thrombosis) emerged as the strongest stroke 
risk factor, but this remains unexplained. Sensitivity analy-
ses limited to only nonhemorrhagic strokes and to the subset 
of participants with no history of cerebrovascular disease at 
baseline were largely similar to the main analysis. Measures 
of glycemia were not predictive of stroke, possibly reflecting 
the relatively narrow range of dysglycemia in NAVIGATOR.
In summary, independent predictors of stroke in patients 
with IGT included not only established risk factors, but also 
other important variables, such as previous venous thrombo-
embolism and elevated waist circumference.
Table 2. Predictors of Stroke in NAVIGATOR Participants in a Multivariable Cox Proportional-Hazard 
Stepwise Selection Model
Baseline Variable* Hazard Ratio (95% CI) P Value
Venous thromboembolism (pulmonary embolism/deep venous thrombosis) 4.09 (2.32–7.22) <0.001
Cerebrovascular disease 2.15 (1.54–3.01) <0.001
Pulse pressure (per 1 mm Hg) 1.02 (1.01–1.03) <0.001
Waist circumference (per 10 cm) 1.28 (1.13–1.46) <0.001
Coronary heart disease 1.67 (1.28–2.19) <0.001
LDL cholesterol (per 1 mmol/L increase between 2.5 and 4.0 mmol/L) 1.44 (1.15–1.80) 0.001
eGFR (per 1 mL min−1 1.73 m−2 up to 70 mL min−1 1.73 m−2) 0.98 (0.96–0.99) 0.006
Heart rate (per bpm up to 70) 0.97 (0.96–0.99) 0.007
Body mass index (per 1 kg/m2) 0.96 (0.92–0.99) 0.01
Age (per 10 y) 1.24 (1.02–1.51) 0.034
Atrial fibrillation 1.65 (1.04–2.63) 0.035
Black vs all other races 2.16 (1.01–4.65) 0.049
Valsartan vs no treatment 0.80 (0.62–1.03) 0.088
Nateglinide vs no treatment 0.88 (0.68–1.13) 0.31
All candidate variables were entered into the model, including closely related groups of variables (for example systolic blood 
pressure, diastolic blood pressure, pulse pressure, and hypertension). CI indicates confidence interval; eGFR, estimated glomerular 
filtration rate; LDL, low-density lipoprotein; and NAVIGATOR, Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes 
Research trial.
*Table includes all independent predictors+randomized treatment (listed above). The model also included other race 
comparisons (white vs all other races; Asian vs all other races), eGFR>70 mL min−1 1.73 m−2, heart rate >70 bpm, and LDL 
cholesterol >4.0 mmol/L (comparisons nonsignificant in this model, data not shown).
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Table I. Definitions of non-fatal and fatal stroke as used in the NAVIGATOR trial  
DEFINITION  SUPPORTIVE DOCUMENTATION  
6.3.1 Stroke  
An acute neurological dysfunction of vascular origin (verified or 
presumed) with clinical signs and / or symptoms that persist for 24 
hours or more.  
 
Types of stroke:  
1. Hemorrhagic stroke: acute neurological deficit with 
documentation of intracranial blood (intraparenchymal, 
intraventricular, subdural, or subarachnoid) preferably by 
neuroimaging (e.g. CT scan or MRI of the brain.) Evidence of 
hemorrhagic stroke can also be obtained from lumbar puncture, 
neurosurgery, or autopsy.  
2. Non-hemorrhagic stroke: acute focal neurologic deficit that 
results from a thrombus or embolus without evidence of 
intracranial blood by neuroimaging (e.g. CT scan or MRI of the 
brain.  
3. Unknown type of stroke: if the type of stroke could not be 
determined due to a lack of imaging or other diagnostic 
information (e.g. lumbar puncture, neurosurgery, or autopsy).  
 
6.3.2 Fatal Stroke  
Autopsy or brain imaging (CT or MRI) confirmed stroke and 
thought to be the primary cause of death. Cessation of life support 
measures (initiated by a direct consequence of the stroke) will be 
classified as death secondary to the stroke.  
Summary of hospitalization (discharge summary)  
Written clinical summary (if the clinical picture is 
not adequately covered in the hospital discharge 
summary)  
Physical examination findings  
Neurological consult report  
CT scan or MRI (original or copy)  
Report of computed tomography, MRI, 
angiography, or other diagnostic procedure  
Autopsy report (if appropriate)  
Surgical/Pathology report of brain  
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Table II. Predictors of stroke in NAVIGATOR participants with no prior history of 
cerebrovascular disease as identified in a multivariable Cox proportional hazard stepwise 
selection model (8,570 participants with 193 events) 
 
Variable* HR (95% CI) P-Value 
Venous thromboembolism (Pulmonary embolism/DVT)  4.62 (2.54–8.38) <0.001 
Waist circumference, per 10 cm 1.36 (1.19–1.56) <0.001 
Coronary heart disease 1.85 (1.37–2.49) <0.001 
LDL-cholesterol, per 1 mmol/L higher between 2.5 and 4.0 mmol/L 1.58 (1.23–2.02) <0.001 
Pulse pressure, per 1 mm Hg 1.02 (1.01–1.03) <0.001 
Age, per 10 yrs 1.44 (1.16–1.77) <0.001 
Heart rate, per 1 bpm up to 70 bpm 0.97 (0.95–0.99) 0.001 
Left ventricular hypertrophy 2.33 (1.32–4.11) 0.004 
BMI, per 1 kg/m2 0.96 (0.92–0.99) 0.02 
Black vs. all other races 2.51 (1.11–5.71) 0.03 
Valsartan vs. no treatment 0.76 (0.57–1.01) 0.06 
Nateglinide vs. no treatment 0.83 (0.63–1.11) 0.20 
 
*Table includes all independent predictors plus randomized treatment (listed above). The model also included other race 
comparisons (white vs. all other races; Asian vs. all other races), heart rate >70bpm and LDL-cholesterol >4.0mmol/L 
(comparisons non-significant in this model, data not shown) 
All candidate variables were entered into the model, including closely related groups of variables (for example systolic blood 
pressure, diastolic blood pressure, pulse pressure, and hypertension).  
BMI indicates body mass index; bpm, beats per minute; CI, confidence interval; DVT, deep venous thrombosis; HR, hazard ratio; 
LDL, low-density lipoprotein. 
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Table III. Predictors of non-hemorrhagic stroke in NAVIGATOR participants as identified in a 
multivariable Cox proportional hazard stepwise selection model (9306 participants with 202 
events) 
 
Variable* HR (95% CI) P-Value 
Cerebrovascular disease 2.43 (1.71-3.44) <0.001 
Venous thromboembolism (Pulmonary embolism/DVT) 3.57 (1.88-6.79) <0.001 
Coronary heart disease 1.69 (1.27-2.27) <0.001 
Pulse pressure, per 1 mm Hg 1.02 (1.01-1.03) <0.001 
eGFR (per 1mL/min/1.73m2 up to 70) 0.97 (0.96-0.99) <0.001 
LDL-cholesterol, per 1 mmol/L higher between 2.5 and 4.0 mmol/L 1.46 (1.14-1.85) 0.002 
Heart rate, per 1 bpm up to 70 bpm 0.97 (0.95-0.99) 0.006 
Waist circumference, per 10 cm 1.15 (1.04-1.28) 0.008 
Female vs. male 0.67 (0.50-0.91) 0.009 
Age, per 10 yrs 1.30 (1.06-1.60) 0.014 
Valsartan vs. no treatment 0.75 (0.57-0.99) 0.041 
Nateglinide vs. no treatment 0.82 (0.62-1.08) 0.15 
 
*Table includes all independent predictors plus randomized treatment (listed above). The model also includes race, eGFR 
>70mL/min/1.73m2, heart rate >70bpm and LDL-cholesterol >4.0mmol/L (comparisons non-significant in this model, data not 
shown) 
All candidate variables were entered into the model, including closely related groups of variables (for example systolic blood 
pressure, diastolic blood pressure, pulse pressure, and hypertension).  
eGFR indicates estimated glomerular filtration rate; bpm, beats per minute; CI, confidence interval; DVT, deep venous 
thrombosis; HR, hazard ratio; LDL, low-density lipoprotein. 
 
